目的 探讨附桂骨痛胶囊联合塞来昔布治疗老年膝关节骨性关节炎的临床疗效。方法 选取许昌市中医院在2016年4月-2017年4月收治的老年膝关节骨性关节炎患者63例，随机分成对照组（31例）和治疗组（32例）。对照组患者口服塞来昔布胶囊，1粒/次，1次/d；治疗组在对照组的基础上口服附桂骨痛胶囊，4粒/次，3次/d。两组患者均治疗4周。评价两组患者临床疗效，同时比较治疗前后两组患者VAS、Lequesne和ADL评分，白细胞介素1β（IL-1β）、基质金属蛋白酶-3（MMP-3）和肿瘤坏死因子-α（TNF-α）水平以及不良反应发生情况。结果 治疗后，对照组和治疗组总有效率分别为77.42%、96.88%；两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者VAS评分、Lequesne评分均明显降低，ADL评分明显升高，同组比较差异具有统计学意义（P<0.05）；且治疗组患者VAS评分、Lequesne评分和ADL评分均明显优于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者IL-1β、MMP-3和TNF-α水平均明显降低（P<0.05）；且治疗组患者各指标水平比对照组降低的更明显（P<0.05）。对照组患者不良反应发生率为25.81%，显著高于治疗组的6.25%，两组比较差异具有统计学意义（P<0.05）。结论 附桂骨痛胶囊联合塞来昔布治疗老年膝关节骨性关节炎疗效显著，安全性较高，具有一定的临床推广应用价值。

Objective To explore the clinical efficacy of Fugui Gutong Capsules combined with celecoxib in treatment of senile knee osteoarthritis. Methods Patients (63 cases) with knee osteoarthritis in Xuchang Hospital of Traditional Chinese Medicine from April 2016 to April 2017 were randomly divided into control (31 cases) and treatment (32 cases) groups. Patients in the control group were po administered with Celecoxib Capsules, 1 grain/time, once daily. Patients in the treatment group were po administered with Fugui Gutong Capsules on the basis of the control group, 4 grains/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacy was evaluated, and the VAS, Lequesne, and ADL scores, IL-1β, MMP-3 and TNF-α levels, and adverse reactions in two groups before and after treatment were compared. Results After treatment, the clinical efficacies in control and treatment groups were 77.42% and 96.88%, respectively, and there was difference between two groups (P<0.05). After treatment, the VAS and Lequesne scores in two groups were significantly decreased, but ADL scores were significantly increased, the difference was statistically significant in the same group (P<0.05). And the VAS, Lequesne and ADL scores in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). After treatment, the IL-1β, MMP-3 and TNF-α levels in two groups were significantly decreased (P<0.05). And these indexes in the treatment group were significantly lower than those in the control group (P<0.05). After treatment, the incidence of adverse reaction in the control group was 25.81%, which was significantly higher than 6.25% in the treatment group, and there were differences between two groups (P<0.05). Conclusion Fugui Gutong Capsules combined with celecoxib has remarkable curative effect in treatment of senile knee osteoarthritis with high safety, which has a certain clinical application value.